Creative Medical Technology Holdings Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Tim Warbington

Algemeen directeur

US$732.7k

Totale compensatie

Percentage CEO-salaris	46.36%
Dienstverband CEO	10.4yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	5.5yrs

Recente managementupdates

Recent updates

Seeking Alpha • May 12

Creative Medical Technology Holdings: Initiating Coverage With A Sell Rating

Summary Initiating coverage on Creative Medical Technology Holdings with a Sell rating due to early-stage pipeline and significant downside risks outweighing potential upside. The company’s pipeline includes AlloStem for diabetes, AlloStemSpine for back pain, and OvaStem for infertility, all in early development with high uncertainty. Financially, Creative Medical has limited cash reserves, high cash burn, and will likely need dilutive financing, posing significant risks to current shareholders. Competing therapies from larger companies in diabetes and back pain markets could overshadow Creative Medical’s offerings, making commercial success uncertain. Read the full article on Seeking Alpha

Analyse CEO-vergoeding

Hoe is Tim Warbington's beloning veranderd ten opzichte van Creative Medical Technology Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2026	n/a	n/a	-US$6m
Dec 31 2025	US$733k	US$340k	-US$6m
Sep 30 2025	n/a	n/a	-US$6m
Jun 30 2025	n/a	n/a	-US$6m
Mar 31 2025	n/a	n/a	-US$6m
Dec 31 2024	US$587k	US$339k	-US$5m
Sep 30 2024	n/a	n/a	-US$5m
Jun 30 2024	n/a	n/a	-US$6m
Mar 31 2024	n/a	n/a	-US$5m
Dec 31 2023	US$523k	US$330k	-US$5m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$469k	US$330k	-US$10m
Sep 30 2022	n/a	n/a	-US$8m
Jun 30 2022	n/a	n/a	-US$9m
Mar 31 2022	n/a	n/a	-US$10m
Dec 31 2021	US$99k	US$99k	US$19m

Compensatie versus markt: De totale vergoeding ($USD 732.72K ) Tim } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 655.15K ).

Compensatie versus inkomsten: De vergoeding van Tim is gestegen terwijl het bedrijf verliesgevend is.

CEO

Tim Warbington (64 yo)

10.4yrs

Tenure

US$732,720

Compensatie

Mr. Timothy Warbington, also known as Tim, is Co-Founder of Creative Medical Technology Holdings, Inc. and serves as its Chief Executive Officer since February 2016 and serves as its President since May 18...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Timothy Warbington	Co-Founder	10.4yrs	US$732.72k	0.33% $ 10.7k
Donald Dickerson	Senior VP	10.4yrs	US$560.00k	0.00046% $ 14.9
Susan Snow	Independent Director	4.6yrs	US$120.00k	geen gegevens
Timothy Henry	Member of Scientific Advisory Board	8.1yrs	geen gegevens	geen gegevens
Boris Reznik	Member of Scientific Advisory Board	5.5yrs	geen gegevens	geen gegevens
Camillo Ricordi	Member of Scientific Advisory Board	5.2yrs	geen gegevens	geen gegevens
Santosh Kesari	Member of Scientific Advisory Board	9.6yrs	geen gegevens	geen gegevens
Michael Finger	Independent Director	4.6yrs	US$80.00k	0.0095% $ 308.7
Bruce Urdang	Independent Director	4.6yrs	US$100.00k	geen gegevens

5.5yrs

Gemiddelde duur

67.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CELZ wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/07/20 15:45
Aandelenkoers aan het einde van de dag	2026/07/20 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Creative Medical Technology Holdings, Inc. wordt gevolgd door 1 analisten. 1 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Jonathan Aschoff	Roth Capital Partners

Creative Medical Technology Holdings Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 18, 2025

Insufficient new directors

Creative Medical Technology Holdings, Inc., Annual General Meeting, Jul 19, 2024

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 20, 2023

High number of new and inexperienced directors

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 19, 2022

Recent updates

Creative Medical Technology Advances Chronic Pain and Osteoarthritis Programs in FDA-Backed Trials

Creative Medical Technology Holdings, Inc. has withdrawn its Follow-on Equity Offering.

Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering.

New minor risk - Share price stability

Creative Medical Technology Holdings Expands Adapt Trial And Advances Toward Phase 3 Planning For Olastrocel In Chronic Lower Back Pain

Creative Medical Technology Holdings Advances Project Phoenix into Nationwide Ai Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards

No longer forecast to breakeven

First quarter 2026 earnings released: US$0.38 loss per share (vs US$0.83 loss in 1Q 2025)

Creative Medical Technology Holdings, Inc. Reports Breakthrough Response Rate in Ultrasome Knee Osteoarthritis Program and Expands CELZ-201 Platform Into Scalable Cell-Free Regenerative Therapies

Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Share price stability

Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from Adapt Trial and Celz-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain

Forecast to breakeven in 2028

Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared Adapt Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point

Creative Medical Technology Holdings Announces World Health Organization Approval of "Olastrocel" as Inn for Lead Allogeneic Cell Therapy Celz-201

No longer forecast to breakeven

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 18, 2025

Creative Medical Technology Holdings Secures FDA Fast Track Designation for CELZ-201-DDT - Advancing Breakthrough Therapy for Chronic Lower Back Pain

Second quarter 2025 earnings released: US$0.48 loss per share (vs US$1.11 loss in 2Q 2024)

New major risk - Market cap size

Creative Medical Technology Holdings: Initiating Coverage With A Sell Rating

New major risk - Shareholder dilution

Creative Medical Technology Holdings Provides Nasdaq Compliance Update

Forecast breakeven date pushed back to 2027

New major risk - Share price stability

Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™

Creative Medical Technology Reports Positive One-Year Results for Allostem™? Type 2 Diabetes Program

Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain

Insufficient new directors

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

New minor risk - Shareholder dilution

Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million.

New minor risk - Share price stability

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Creative Medical Technology Holdings, Inc., Annual General Meeting, Jul 19, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access

Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem

New major risk - Financial position

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 20, 2023

Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain

Creative Medical Technology Holdings Receives FDA Clearance to Initiate A Phase 1/2 Clinical Trial of Stemspine® Using Allostem™ (Celz-201-Ddt) for the Treatment of Chronic Lower Back Pain

Creative Medical Technology Holdings Regains Compliance with Nasdaq Listing Requirements

Creative Medical Technology Holdings, Inc. (NasdaqCM:CELZ) announces an Equity Buyback for $2 million worth of its shares.

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of Its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz(R) Immunotherapy Platform

Creative Medical Technology Holdings, Inc. Announces Next Milestone Achievements in ImmCelz Platform Development

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

Creative Medical Technology Holdings, Inc. Announces Positive Three-Year Follow-Up Data for the Company's Stemspine Pilot Study

Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

High number of new and inexperienced directors

Creative Medical Technology Holdings, Inc. Announces Fda Clearance of Investigational New Drug (Ind) Application for Allostem(Tm), A Novel Cell Therapy for the Treatment of Type 1 Diabetes

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 19, 2022

Creative Medical Technology Holdings, Inc. Develops AlloStem Clinical Cell Line

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Creative Medical Technology Holdings Receives Non-Compliance Notice from Nasdaq

Creative Medical Technology Holdings, Inc. announced that it has received $17.000001 million in funding

High number of new and inexperienced directors

Creative Medical Technology Holdings, Inc. Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

High number of new and inexperienced directors

Creative Medical Technology Holdings Deleted from Other OTC

Less than half of directors are independent

Creative Medical Technology Holdings, Inc. announced that it has received $3.78775 million in funding

Creative Medical Technology Holdings, Inc. announced that it expects to receive $3.788 million in funding

Creative Medical Technology Holdings Identifies Synergy Between Immcelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 Diabetes

Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's Disease

FDA Responds to Creative Medical Technology Holdings, Inc. Regarding its ImmCelz® IND for Stroke Treatment